6,7,8,9-tetrahydro-1H,3H,5H-cycloheptapyrimidin-2,4-dione | 53476-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6,7,8,9-tetrahydro-1H,3H,5H-cycloheptapyrimidin-2,4-dione
• 英文别名: 5,6-Pentamethylen-uracil；1,5,6,7,8,9-hexahydro-cycloheptapyrimidine-2,4-dione；6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidine-2,4-diol；1,5,6,7,8,9-hexahydrocyclohepta[d]pyrimidine-2,4-dione
• CAS: 53476-71-4
• 化学式: C₉H₁₂N₂O₂
• 分子量: 180.206
• InChiKey: PXILTEYPVYROAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  6,7,8,9-tetrahydro-1H,3H,5H-cycloheptapyrimidin-2,4-dione 在 ammonium hydroxide 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 生成 2-chloro-6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-4-amine
  参考文献：
  名称：

  Sekiya; Hiranuma; Kanayama, European Journal of Medicinal Chemistry, 1980, vol. 15, # 4, p. 317 - 322

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氧代-1-环庚烷甲酸甲酯 在 sodium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 28.0h， 生成 6,7,8,9-tetrahydro-1H,3H,5H-cycloheptapyrimidin-2,4-dione
  参考文献：
  名称：

  一种医药中间体环烷烃并嘧啶二酮化合物的 合成方法

  摘要：

  本发明提供了一种环烷烃并嘧啶二酮化合物的合成方法，属于有机合成技术领域。本发明所提供的方法为以2‑甲氧羰基环烷酮化合物为原料，在碱存在下与S‑甲基异硫脲硫酸盐在水中发生关环反应，反应完成后调节pH生成悬浊液，过滤得到2‑甲硫基‑4羟基环烷烃并嘧啶化合物粗品，粗品再在酸催化剂的存在下发生水解反应，反应完成后通过热滤、溶剂洗涤、真空浓缩、析晶、过滤、水洗、烘干等操作得到目标产物环烷烃并嘧啶二酮化合物。本发明的合成方法收率高、操作简便、对设备和环境友好，适用于环烷烃并嘧啶二酮化合物的高效合成。

  公开号：

  CN112028839B

文献信息

• New procedures for the synthesis of heterocyclic substituted and 2,4-difunctionalized pyrimidines
  作者：Antonio García Martínez、Antonio Herrera Fernández、Florencio Moreno Jiménez、Pablo J Muñoz Martínez、Cristina Alonso Martín、Laksminarayanapuran R Subramanian

  DOI：10.1016/0040-4020(96)00368-7

  日期：1996.6

  N-tosyl-2-pyrrolidone 5 were condensed with cyano compounds in the presence of triflic anhydride (Tf2O) to yield heteroarylpyrimidines. 2,4-Difunctionalized pyrimidines were obtained by reaction of the corresponding 2,4-bis(methylsulfonyl)pyrimidines with nucleophiles.

  在三氟甲酸酐（Tf 2 O）存在下，将N-甲苯磺酰基-2-和-3-乙酰基吡咯1或N-甲苯磺酰基-2-吡咯烷酮5与氰基化合物缩合，得到杂芳基嘧啶。通过使相应的2，4-双（甲基磺酰基）嘧啶与亲核试剂反应获得2，4-双官能化的嘧啶。
• FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20140179668A1

  公开（公告）日：2014-06-26

  Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.

  提供了融合嘧啶化合物作为激酶抑制剂，如多激酶抑制剂。提供了融合嘧啶化合物作为IGF-IR抑制剂。这些化合物可用于治疗癌症的方法。还提供了含有融合嘧啶化合物和药用载体的药物组合物，以及含有融合嘧啶化合物或其盐和使用说明的试剂盒，例如用于治疗癌症的方法。
• COMPOUNDS AND THERAPEUTICAL USE THEREOF
  申请人：ANDERSON MARK B.

  公开号：US20100069383A1

  公开（公告）日：2010-03-18

  Disclosed are 4-arylamino-quinazolines and analogs thereof that are effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳基氨基喹唑啉及其类似物，其作为caspase的激活剂和诱导凋亡剂具有有效性。该发明的化合物在治疗各种临床病症中有用，其中不受控制的异常细胞生长和扩散发生。
• COMPOUNDS AND THERAPEUTICAL USES THEREOF
  申请人：Myrexis, Inc.

  公开号：US20130029942A1

  公开（公告）日：2013-01-31

  Disclosed are 4-arylamino-quinazolines and analogs thereof that are effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳基氨基喹唑啉及其类似物，它们有效地激活半胱氨酸蛋白酶并诱导细胞凋亡。该发明的化合物在治疗各种临床病症中具有用途，其中包括发生异常细胞无控制生长和扩散的情况。
• Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer
  作者：Xueyuan Wang、Enhe Bai、Hui Zhou、Sijia Sha、Hang Miao、Yanru Qin、Zhaogang Liu、Jia Wang、Haoyang Zhang、Meng Lei、Jia Liu、Ou Hai、Yongqiang Zhu

  DOI：10.1016/j.bmc.2018.12.036

  日期：2019.2

  Valosine containing protein (VCP/p97) is a member of the AAA ATPase family involved in several essential cellular functions and plays an important role in the ubiquitin-mediated degradation of misfolded proteins. P97 has a significant role in maintaining the cellular protein homeostasis for tumor cell growth and survival and has been found overexpressed in many tumor types. No new molecule entities based on p97 target were approved in clinic. Herein, a series of novel pyrimidine structures as p97 inhibitors were designed and synthesized. After enzymatic evaluations, structure-activity relationships (SAR) were discussed in detailed. Among the screened compounds, derivative 35 showed excellent enzymatic inhibitory activity (IC50, 36 nM). The cellular inhibition results showed that compound 35 had good antiproliferative activity against the non-small cell lung cancer A549 cells (IC50, 1.61 mu M). Liver microsome stability showed that the half-life of compound 35 in human liver microsome was 42.3 min, which was more stable than the control CB-5083 (25.8 min). The in vivo pharmacokinetic results showed that the elimination phase half-lives of compound 35 were 4.57 h for ig and 3.64 h for iv, respectively and the oral bioavailability was only 4.5%. These results indicated that compound 35 could be effective for intravenous treatment of non-small cell lung cancer.